Elicio Therapeutics (ELTX) EVP Haqq granted 25,400 RSUs and 50,900 options

Rhea-AI Filing Summary

Elicio Therapeutics, Inc. granted equity awards to executive Christopher Haqq, Executive Vice President, Head of R&D and Chief Medical Officer. On February 2, 2026, he received 25,400 restricted stock units (RSUs) of common stock at $0 cost and a stock option for 50,900 shares with an exercise price of $8.1 per share.

The 25,400 RSUs vest 25% on February 2, 2027, then annually over three additional years, contingent on continued service. The 50,900 options vest 25% on February 2, 2027, with the remainder vesting monthly over the following three years. After these grants, he directly holds 57,381 common shares and 50,900 options.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Haqq Christopher

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	50,900	$0.00	--
Grant/Award	Common Stock	25,400	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 50,900 shares (Direct); Common Stock — 57,381 shares (Direct)

Footnotes (1)

1. Represents restricted stock units ("RSUs") that will vest as to 25% of the RSUs on February 2, 2027, the first anniversary of the grant date, with the remaining RSUs vesting in annual installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Each RSU represents the right to receive one share of common stock, par value $0.01 per share, of the Issuer. The stock option vests and becomes exercisable as to 25% of the options on February 2, 2027, the first anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Haqq Christopher

(Last) (First) (Middle)

C/O ELICIO THERAPEUTICS, INC.

451 D STREET, 5TH FLOOR, SUITE 501

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elicio Therapeutics, Inc. [ ELTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		A		25,400(1)	A	$0(1)	57,381	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.1	02/02/2026		A		50,900		(2)	02/02/2036	Common Stock	50,900	$0	50,900	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs") that will vest as to 25% of the RSUs on February 2, 2027, the first anniversary of the grant date, with the remaining RSUs vesting in annual installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Each RSU represents the right to receive one share of common stock, par value $0.01 per share, of the Issuer.

2. The stock option vests and becomes exercisable as to 25% of the options on February 2, 2027, the first anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Remarks:

Executive Vice President, Head of R&D and Chief Medical Officer

	/s/ Christopher Haqq	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ELTX executive Christopher Haqq report?

Christopher Haqq reported grants of equity awards, not sales. He received 25,400 restricted stock units (RSUs) and a stock option for 50,900 shares of Elicio Therapeutics common stock, both awarded on February 2, 2026 as part of his compensation.

How many Elicio Therapeutics (ELTX) shares does Christopher Haqq now own directly?

After the reported transaction, Christopher Haqq directly owns 57,381 shares of ELTX common stock. This figure reflects his beneficial ownership of non-derivative common stock following the grant of 25,400 RSUs on February 2, 2026, as disclosed in the filing.

What are the key terms of Christopher Haqq’s ELTX stock option grant?

Haqq received a stock option for 50,900 ELTX shares with an exercise price of $8.1 per share. 25% of the options vest on February 2, 2027, with the remaining options vesting in monthly installments over the following three years, subject to continued service.

How do the ELTX RSUs granted to Christopher Haqq vest over time?

The 25,400 RSUs vest 25% on February 2, 2027, the first anniversary of the grant date. The remaining RSUs vest in annual installments over three additional years, conditioned on Haqq’s continued service with Elicio Therapeutics through each vesting date.

What role does Christopher Haqq hold at Elicio Therapeutics (ELTX)?

Christopher Haqq serves as Elicio Therapeutics’ Executive Vice President, Head of R&D and Chief Medical Officer. The reported RSU and stock option grants on February 2, 2026 appear to be equity-based compensation associated with his senior leadership position.

Are the reported ELTX equity awards to Christopher Haqq immediately fully vested?

No, the awards are time-based and subject to vesting. Both the 25,400 RSUs and the 50,900 stock options vest over four years starting on February 2, 2027, and require Haqq’s continued service with Elicio Therapeutics to fully vest.